Want to see GB:SAR full AI Analyst Report?
Sareum Holdings (SAR) AI Stock Analysis
Sareum Holdings
(LSE:SAR)
Weak financials with cash burn and no revenue dominate as primary risk, partially offset by strong technical momentum and moderate valuation for biotech stage.
Sareum Holdings (SAR) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 21.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 435.83K
- Price to Earnings (P/E)
- -4.2
- Beta (1Y)
- -0.22
- Revenue Growth
- ―
- EPS Growth
- -105.65%
- Country
- UK
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sareum Holdings Business Overview & Revenue Model
Company Description
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizin...
How the Company Makes Money
Sareum’s business model is typical of an early-stage drug development company: it invests in internal research to create proprietary drug candidates and seeks to generate returns primarily through partnering transactions rather than product sales. Ke...
Sareum Holdings Financial Statement Overview
Summary
Low score reflects weak income statement (15) with no revenue and rising losses, poor cash flow (25) due to ongoing burn, offset slightly by strong balance sheet (45) with zero debt and growing equity.
Income Statement
15Very NegativeBalance Sheet
45NeutralCash Flow
25Negative| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -1,000 | -1,000 | -2,000 | -1,088 |
| EBITDA | -5.40M | -3.38M | -4.54M | -4.01M | -2.57M | -1.70M |
| Net Income | -4.93M | -4.44M | -3.42M | -3.19M | -2.17M | -1.50M |
Balance Sheet | ||||||
| Total Assets | 3.23M | 4.23M | 2.77M | 2.02M | 4.79M | 3.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.49M | 3.55M | 1.46M | 994.00K | 4.26M | 2.69M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.04M | 1.95M | 653.00K | 867.00K | 455.00K | 284.15K |
| Stockholders Equity | 1.19M | 2.28M | 2.11M | 1.15M | 4.33M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Operating Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Investing Cash Flow | 12.00K | 89.00K | 9,000 | -41.00K | -2,000 | -37.86K |
| Financing Cash Flow | 1.58M | 4.55M | 4.38M | 0 | 3.71M | 2.49M |
Sareum Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SAR, the sentiment is Negative. The current price of 15.49 is below the 20-day moving average (MA) of 24.00, below the 50-day MA of 28.80, and below the 200-day MA of 22.30, indicating a bearish trend. The MACD of -3.68 indicates Positive momentum. The RSI at 9.22 is Positive, neither overbought nor oversold. The STOCH value of 8.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SAR.
Sareum Holdings Peers Comparison
Overall Rating
GB:FAB49Neutral- GB:SAR49Neutral
GB:POLB46Neutral
GB:IMM43Neutral
GB:AREC41Neutral
GB:APTA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:FAB | 49Neutral | GBP 7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% |
| GB:SAR | 49Neutral | GBP 24.95M | -4.19 | -284.01% | ― | ― | -105.65% |
| GB:POLB | 46Neutral | GBP 49.62M | -8.21 | -71.28% | ― | ― | 31.58% |
| GB:IMM | 43Neutral | GBP 20.28M | -2.65 | -559.87% | ― | ― | 5.62% |
| GB:AREC | 41Neutral | GBP 37.37M | 165.00 | 3.75% | ― | ― | ― |
| GB:APTA | 37Underperform | GBP 10.23M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SAR | Sareum Holdings | 15.25 | 0.25 | 1.67% | |
| GB:IMM | ImmuPharma plc | 3.31 | -6.69 | -66.85% | |
| GB:FAB | Fusion Antibodies Plc | 6.00 | -6.75 | -52.94% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.40 | 2.65 | 70.67% | |
| GB:AREC | Arecor Therapeutics PLC | 82.50 | 10.00 | 13.79% | |
| GB:APTA | Aptamer Group Plc | 0.28 | -0.53 | -65.24% |
Sareum Holdings Corporate Events
Sareum Completes Key Toxicology Milestone for Autoimmune Drug Candidate SDC-1801
PositiveSareum Holdings has completed dosing in its Phase 2-enabling toxicology programme for SDC-1801, a selective oral TYK2/JAK1 inhibitor being developed for autoimmune diseases with an initial focus on psoriasis. The company is now analysing the data and...
Sareum’s SDC-1801 Phase 1 Data Published, Paving Way for Phase 2-Ready Package
PositiveSareum Holdings has published the full Phase 1 clinical dataset for its lead TYK2/JAK1 inhibitor SDC-1801 in the British Journal of Clinical Pharmacology, reinforcing its positioning as a developer of best-in-class oral therapies for autoimmune disea...
Sareum Adds £62,500 via Warrant Exercise as Share Count Rises
PositiveSareum Holdings has received notice for the exercise of warrants over 500,000 new ordinary shares at 12.5 pence each, raising £62,500 in fresh equity capital. Application has been made for the new shares to be admitted to trading on AIM, where t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jun 01, 2026